Dilated Cardiomyopathy - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Dilated Cardiomyopathy - Pipeline Review, H1 2019’, provides an overview of the Dilated Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy

- The report reviews pipeline therapeutics for Dilated Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Dilated Cardiomyopathy therapeutics and enlists all their major and minor projects

- The report assesses Dilated Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Array BioPharma Inc

Capricor Therapeutics Inc

Celixir Ltd

Hemostemix Inc

Martin Pharmaceuticals Inc

MyoKardia Inc

Array BioPharma Inc

Capricor Therapeutics Inc

Celixir Ltd

Hemostemix Inc

Martin Pharmaceuticals Inc

MyoKardia Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dilated Cardiomyopathy - Overview

Dilated Cardiomyopathy - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dilated Cardiomyopathy - Overview

Dilated Cardiomyopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Dilated Cardiomyopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dilated Cardiomyopathy - Companies Involved in Therapeutics Development

Array BioPharma Inc

Capricor Therapeutics Inc

Celixir Ltd

Hemostemix Inc

Martin Pharmaceuticals Inc

MyoKardia Inc

Dilated Cardiomyopathy - Drug Profiles

ACP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heartcel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUS-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-440181 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dilated Cardiomyopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trimetazidine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YS-1402 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dilated Cardiomyopathy - Dormant Projects

Dilated Cardiomyopathy - Product Development Milestones

Featured News & Press Releases

Dec 11, 2018: MyoKardia reports positive data from phase 1b single-ascending dose clinical trial of MYK-491 in dilated cardiomyopathy and systolic heart failure patients

Dec 06, 2018: Berlin Cures steering committee is assembled to facilitate the design and implementation of phase 2 study of BC 007

Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day

Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study

Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients

Nov 02, 2017: MyoKardia Provides Update on MYK-491

Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress

Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491

Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491

Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress

Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Dilated Cardiomyopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for Dilated Cardiomyopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc, H1 2019

Dilated Cardiomyopathy - Pipeline by Capricor Therapeutics Inc, H1 2019

Dilated Cardiomyopathy - Pipeline by Celixir Ltd, H1 2019

Dilated Cardiomyopathy - Pipeline by Hemostemix Inc, H1 2019

Dilated Cardiomyopathy - Pipeline by Martin Pharmaceuticals Inc, H1 2019

Dilated Cardiomyopathy - Pipeline by MyoKardia Inc, H1 2019

Dilated Cardiomyopathy - Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Dilated Cardiomyopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Dilated Cardiomyopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports